2020
Association of T- and B-cell receptor repertoires with molecular subtypes and outcome in HER2+ breast cancer: An analysis of the NeoALTTO clinical trial.
Rediti M, Venet D, Rothe F, Qing T, Maetens M, Bradbury I, Izquierdo M, Di Cosimo S, Hilbers F, Bajji M, Harbeck N, Untch M, Liu M, Saura C, Huober J, Nuciforo P, Salgado R, Loi S, Pusztai L, Sotiriou C. Association of T- and B-cell receptor repertoires with molecular subtypes and outcome in HER2+ breast cancer: An analysis of the NeoALTTO clinical trial. Journal Of Clinical Oncology 2020, 38: 511-511. DOI: 10.1200/jco.2020.38.15_suppl.511.Peer-Reviewed Original ResearchPathological complete responseBreast cancerPAM50 subtypesB cell receptorImmune responseBiomarker-driven treatment strategiesTumor-infiltrating lymphocyte levelsBaseline tumor biopsiesEvent-free survivalPhase III trialsAnti-HER2 treatmentGrade 3 tumorsEstrogen receptor statusImproved clinical outcomesProportional hazards modelIII trialsLymphocyte levelsComplete responseReceptor statusClinical outcomesClinicopathological characteristicsBC subtypesClinical trialsTreatment strategiesTumor biopsiesEarly Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy
Di Cosimo S, Appierto V, Pizzamiglio S, Silvestri M, Baselga J, Piccart M, Huober J, Izquierdo M, de la Pena L, Hilbers FS, de Azambuja E, Untch M, Pusztai L, Pritchard K, Nuciforo P, Vincent-Salomon A, Symmans F, Apolone G, de Braud FG, Iorio MV, Verderio P, Daidone MG. Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy. International Journal Of Molecular Sciences 2020, 21: 1386. PMID: 32085669, PMCID: PMC7073028, DOI: 10.3390/ijms21041386.Peer-Reviewed Original ResearchConceptsPathological complete responseNeoadjuvant therapyHER2-positive breast cancer patientsTrastuzumab-based neoadjuvant therapyAvailable predictive biomarkersBreast cancer patientsEstrogen receptor statusComplete responseReceptor statusCancer patientsPredictive biomarkersTreatment responseHCC progressionPatientsPredictive valueBivariate analysisMean differencePlasma pairsTherapyEarly modulationMicroRNA levelsTrastuzumabMAPK signalingMetabolism regulationKEGG analysis
2017
Bone metastasis-related signaling pathways in breast cancers stratified by estrogen receptor status
Hayashi N, Iwamoto T, Qi Y, Niikura N, Santarpia L, Yamauchi H, Nakamura S, Hortobagyi GN, Pusztai L, Symmans WF, Ueno NT. Bone metastasis-related signaling pathways in breast cancers stratified by estrogen receptor status. Journal Of Cancer 2017, 8: 1045-1052. PMID: 28529618, PMCID: PMC5436258, DOI: 10.7150/jca.13690.Peer-Reviewed Original ResearchER-negative breast cancerEstrogen receptor statusBone metastasesER statusBreast cancerReceptor statusHuman epidermal growth factor receptor 2Breast cancer bone metastasisEpidermal growth factor receptor 2Cox proportional hazards modelNon-bone metastasisGrowth factor receptor 2Cancer bone metastasisProportional hazards modelBreast cancer specimensInvasive breast cancer specimensFactor receptor 2Negative cohortCancer specimensHazards modelReceptor 2BCBMMetastasisCancerCohort
2012
172O ER + /HER2+ and ER-/Her2+ Breast Cancers are Molecularly Distinct but Immune Gene Signatures are Prognostic and Predictive in Both Groups
Iwamoto T, Pusztai L, Matsuoka J, Callari M, Kelly C, Qi Y, Motoki T, Taira N, Santarpia L, Doihara H, Gianni L, Bianchini G. 172O ER + /HER2+ and ER-/Her2+ Breast Cancers are Molecularly Distinct but Immune Gene Signatures are Prognostic and Predictive in Both Groups. Annals Of Oncology 2012, 23: ix74-ix75. DOI: 10.1016/s0923-7534(20)32783-6.Peer-Reviewed Original ResearchPathologic complete responseER statusResidual diseaseER-/HER2HER2 cancersBetter prognosisBreast cancerHER2-positive breast cancerImmune gene signaturesSystemic adjuvant therapyPositive breast cancerEstrogen receptor statusHigher chemotherapy sensitivityDistinct molecular subtypesNeoadjuvant taxaneAdjuvant therapyImmune signaturesComplete responseReceptor statusHER2 patientsPoor prognosisMolecular subtypesChemotherapy sensitivityPredictive valueHER2
2010
Stability of estrogen receptor status in breast carcinoma
Gong Y, Han EY, Guo M, Pusztai L, Sneige N. Stability of estrogen receptor status in breast carcinoma. Cancer 2010, 117: 705-713. PMID: 20939012, DOI: 10.1002/cncr.25506.Peer-Reviewed Original ResearchConceptsER statusBreast carcinomaEndocrine therapyMetastatic sitesPrimary tumorMetastatic tumorsMetastatic breast carcinomaEstrogen receptor statusER discordanceDisease courseReceptor statusSystemic therapyClinical courseER expressionER testingClinical managementNegative conversionER assaysDiscordant casesCarcinomaPositive conversionTumorsPatientsMetastasisTherapy
2009
Evaluation of the Predictive Performance and Regimen Specificity of a 30-Gene Predictor of Pathologic Complete Response in a Prospective Randomized Neoadjuvant Clinical Trial for Stage I-III Breast Cancer.
Tabchy A, Symmans W, Valero V, Vidaurre T, Lluch A, Qi Y, Souchon E, Barajas-Figueroa L, Gomez H, Martin M, Coutant C, Hess K, Hortobagyi G, Pusztai L. Evaluation of the Predictive Performance and Regimen Specificity of a 30-Gene Predictor of Pathologic Complete Response in a Prospective Randomized Neoadjuvant Clinical Trial for Stage I-III Breast Cancer. Cancer Research 2009, 69: 101-101. DOI: 10.1158/0008-5472.sabcs-09-101.Peer-Reviewed Original ResearchPathologic complete responsePositive predictive valueCourses of FACFAC armWeekly paclitaxelFAC chemotherapyPCR rateComplete responseMultigene predictorsTreatment armsBreast cancerStage IPathologic complete response rateGenomic predictorsComplete response rateNeoadjuvant clinical trialsEstrogen receptor statusNegative predictive value 88Treatment response predictionFAC regimenNPV 92Neoadjuvant chemotherapyOnly chemotherapyCyclophosphamide chemotherapyNodal statusEradication of Axillary Lymph Node Metastases Occurs in 74% of Patients Receiving Neoadjuvant Chemotherapy with Concurrent Trastuzumab for HER2 Positive Breast Cancer.
Dominici L, Negron Gonzalez V, Buzdar A, Lucci A, Mittendorf E, Pusztai L, Krishnamurthy S, Le-Petross H, Babiera G, Bedrosian I, Meric-Bernstam F, Hunt K, Valero V, Kuerer H. Eradication of Axillary Lymph Node Metastases Occurs in 74% of Patients Receiving Neoadjuvant Chemotherapy with Concurrent Trastuzumab for HER2 Positive Breast Cancer. Cancer Research 2009, 69: 1086-1086. DOI: 10.1158/0008-5472.sabcs-09-1086.Peer-Reviewed Original ResearchAxillary pathologic complete responseTrastuzumab-based neoadjuvant chemotherapyPathologic complete responseDisease-free survivalHER2-positive breast cancerHER2-positive diseaseResidual axillary diseaseNeoadjuvant chemotherapyPositive breast cancerAxillary metastasesPCR groupAxillary diseasePositive diseaseBreast cancerComplete axillary lymph node dissectionAxillary lymph node dissectionAxillary lymph node metastasisComplete pathologic responseLymph node dissectionKaplan-Meier methodMajority of patientsKaplan-Meier analysisLymph node metastasisEstrogen receptor statusConcurrent trastuzumab
2007
HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer
Andre F, Mazouni C, Liedtke C, Kau SW, Frye D, Green M, Gonzalez-Angulo AM, Symmans WF, Hortobagyi GN, Pusztai L. HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer. Breast Cancer Research And Treatment 2007, 108: 183-190. PMID: 17468948, DOI: 10.1007/s10549-007-9594-8.Peer-Reviewed Original ResearchMeSH KeywordsAntigens, NeoplasmAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsCyclophosphamideDisease-Free SurvivalDNA Topoisomerases, Type IIDNA-Binding ProteinsDoxorubicinDrug Administration ScheduleFemaleFluorouracilGene AmplificationGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMiddle AgedNeoadjuvant TherapyNeoplasm StagingOligonucleotide Array Sequence AnalysisPaclitaxelPatient SelectionPoly-ADP-Ribose Binding ProteinsReceptor, ErbB-2Receptors, EstrogenRetrospective StudiesRNA, MessengerTau ProteinsTime FactorsTreatment OutcomeConceptsPathologic complete responseHER2 overexpressionBreast cancerFAC chemotherapyPCR rateER statusHER2 expressionRelapse-free survival rateHER2-overexpressing breast cancerMicrotubule associated protein tauER-positive cancersEstrogen receptor statusPreoperative chemotherapyComplete responseHER2 tumorsMethodsRetrospective analysisReceptor statusPatientsSurvival rateMultivariate analysisWeekly scheduleMAP-tauProtein tauCancerChemotherapyDetermination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study
Gong Y, Yan K, Lin F, Anderson K, Sotiriou C, Andre F, Holmes FA, Valero V, Booser D, Pippen JE, Vukelja S, Gomez H, Mejia J, Barajas LJ, Hess KR, Sneige N, Hortobagyi GN, Pusztai L, Symmans WF. Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study. The Lancet Oncology 2007, 8: 203-211. PMID: 17329190, DOI: 10.1016/s1470-2045(07)70042-6.Peer-Reviewed Original ResearchConceptsEstrogen receptor status
2006
Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer
Hess KR, Anderson K, Symmans WF, Valero V, Ibrahim N, Mejia JA, Booser D, Theriault RL, Buzdar AU, Dempsey PJ, Rouzier R, Sneige N, Ross JS, Vidaurre T, Gómez HL, Hortobagyi GN, Pusztai L. Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer. Journal Of Clinical Oncology 2006, 24: 4236-4244. PMID: 16896004, DOI: 10.1200/jco.2006.05.6861.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsCyclophosphamideDoxorubicinFemaleFluorouracilGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMicroarray AnalysisMiddle AgedNeoplasm StagingOligonucleotidesPaclitaxelPredictive Value of TestsReproducibility of ResultsROC CurveSensitivity and Specificity
2005
Nomograms to Predict Pathologic Complete Response and Metastasis-Free Survival After Preoperative Chemotherapy for Breast Cancer
Rouzier R, Pusztai L, Delaloge S, Gonzalez-Angulo AM, Andre F, Hess KR, Buzdar AU, Garbay JR, Spielmann M, Mathieu MC, Symmans WF, Wagner P, Atallah D, Valero V, Berry DA, Hortobagyi GN. Nomograms to Predict Pathologic Complete Response and Metastasis-Free Survival After Preoperative Chemotherapy for Breast Cancer. Journal Of Clinical Oncology 2005, 23: 8331-8339. PMID: 16293864, DOI: 10.1200/jco.2005.01.2898.Peer-Reviewed Original ResearchMeSH KeywordsAnthracyclinesAntibiotics, AntineoplasticAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsChemotherapy, AdjuvantDecision Making, Computer-AssistedDisease-Free SurvivalFemaleFranceHumansInternetLogistic ModelsMiddle AgedMultivariate AnalysisNeoadjuvant TherapyNomogramsPaclitaxelPredictive Value of TestsProportional Hazards ModelsReproducibility of ResultsTexasConceptsDistant metastasis-free survivalPathologic complete responseMetastasis-free survivalPreoperative chemotherapyComplete responseCox proportional hazards regression modelProportional hazards regression modelsM.D. Anderson Cancer CenterPreoperative chemotherapy cyclesSchedule of paclitaxelCombination of paclitaxelEstrogen receptor statusHazards regression modelsMultivariate logistic regressionInstitut Gustave RoussyAnderson Cancer CenterInclusion of paclitaxelClinical prediction modelChemotherapy cyclesReceptor statusClinical stageClinical variablesHistologic gradeCancer CenterPrediction nomogramBreast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy
Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, Hess KR, Stec J, Ayers M, Wagner P, Morandi P, Fan C, Rabiul I, Ross JS, Hortobagyi GN, Pusztai L. Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy. Clinical Cancer Research 2005, 11: 5678-5685. PMID: 16115903, DOI: 10.1158/1078-0432.ccr-04-2421.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBiopsy, NeedleBreastBreast NeoplasmsCluster AnalysisDoxorubicinFemaleFluorouracilGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMiddle AgedMultivariate AnalysisOligonucleotide Array Sequence AnalysisPaclitaxelPredictive Value of TestsPreoperative CareReceptor, ErbB-2ConceptsPathologic complete responseComplete responsePreoperative chemotherapyBreast cancerEstrogen receptor-negative subtypesPathologic CR rateEstrogen receptor statusBasal-like groupDifferent molecular subtypesFine-needle aspirationAffymetrix U133A microarraysPreoperative paclitaxelCyclophosphamide chemotherapyReceptor statusCR rateLuminal tumorsDifferent prognosisNuclear gradeMolecular subtypesNeedle aspirationChemotherapy sensitivityChemotherapyCancerMolecular classificationHuman tumorsThe Role of Sigma Receptor in Breast Cancer
Pusztai L. The Role of Sigma Receptor in Breast Cancer. 2005 DOI: 10.21236/ada436919.Peer-Reviewed Original ResearchBreast cancerSKF 10047MRNA expressionCell linesEstrogen receptor statusBreast cancer cell linesCell migrationCancer cell linesReceptor statusLymph nodesSigma receptorsMDA-435 cellsMDA-231Western blotLigand exposureCancerCell proliferationCorrelative studiesNegative resultsSignaling pathwaysSiRNA technologyGene expression analysisActivity of RhoMolecular mechanismsExposure
2004
Her2/neu-positive disease does not increase risk of locoregional recurrence for patients treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy, and radiotherapy
Buchholz TA, Huang EH, Berry D, Pusztai L, Strom EA, McNeese MD, Perkins GH, Schechter NR, Kuerer HM, Buzdar AU, Valero V, Hunt KK, Hortobagyi GN, Sahin AA. Her2/neu-positive disease does not increase risk of locoregional recurrence for patients treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy, and radiotherapy. International Journal Of Radiation Oncology • Biology • Physics 2004, 59: 1337-1342. PMID: 15275718, DOI: 10.1016/j.ijrobp.2004.02.018.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntibiotics, AntineoplasticBreast NeoplasmsChemotherapy, AdjuvantClinical Trials as TopicConfidence IntervalsDoxorubicinDrug Resistance, NeoplasmFemaleHumansLymphatic MetastasisMastectomy, RadicalNeoadjuvant TherapyNeoplasm ProteinsNeoplasm Recurrence, LocalRadiation ToleranceReceptor, ErbB-2Receptors, EstrogenRegression AnalysisRetrospective StudiesConceptsHER2/neu-positive diseaseHER2/neu-positive tumorsLocoregional recurrenceHER2/neuNeoadjuvant doxorubicinHER2/neu-negative diseaseHER2/neu-negative tumorsEstrogen receptor-negative diseaseHER2/neu positivityHER2/neu overexpressionChest wall boostNeu-negative tumorsOverall LRR ratePositive lymph nodesReceptor-negative diseaseCox regression analysisEstrogen receptor statusLRR rateSupraclavicular diseaseHazard ratioLymph nodesReceptor statusPostmastectomy radiotherapyPreclinical dataNeu overexpression